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In this study, we investigated all Clostridioides difficile strains isolated from stool 25 
samples in Nagasaki University Hospital between January 2012 and December 2014. 26 
Toxin genes (tcdA, tcdB and cdtA/cdtB) were analyzed for multiplex PCR in a total of 27 
213 strains. In the toxin gene-positive strain, PCR ribotyping was conducted using 28 
capillary gel electrophoresis-based PCR and the Webribo database. Patients’ 29 
backgrounds were analyzed by departments, disorders, antimicrobials, and clinical 30 
dates. The positive rates of tcdA, tcdB, and cdtA/cdtB genes were 62.9%, 63.4%, and 31 
2.8%, respectively. The most frequent PCR ribotype was 047 (14.1%), followed by 32 
014/0 (11.1%) and 002/0 (8.2%). In univariate analysis, the risk factors for the detection 33 
of toxin gene-positive strains in patients were older age (p = 0.0036), over ≥ 65 years 34 
old (p = 0.0175), the patients hospitalized at Department of Digestive Surgery (P = 35 
0.0059), higher CRP level (P = 0.0395), and lower albumin level (p = 0.0014). In the 36 
multivariate analysis, the risk factor for detection of toxin gene-positive strains was the 37 
patients hospitalized at Department of Digestive Surgery (OR; 4.62, 95% CI; 1.18-18.0, 38 
p = 0.0274). In this study, the percentage of toxin gene-positive and cdtA/cdtB gene-39 
positive strains was almost the same as that reported in previous studies, but the 40 
ribotype was different. In addition, we revealed that the risk factor associated with 41 
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the detection of toxin gene-positive strains was the patients hospitalized at 42 
Department of digestive surgery. 43 
 44 
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 Clostridioides difficile is a gram-positive anaerobic bacterium and a causative 48 
pathogen of antibiotic-associated diarrhea (AAC) [1]. In C. difficile infections (CDIs), 49 
toxin A and B play important roles [2,3]. Both toxins have cytotoxic activities and 50 
induce the release of various immunomodulatory mediators from epithelial cells, 51 
phagocytes, and mast cells [2]. Recently, the spread of binary toxin (CDT)-producing 52 
strains has raised a major concern in the United States and Europe. CDT-producing 53 
strains are highly resistant to fluoroquinolones and increase mortality [4–6]. In 54 
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 55 
guideline for the diagnosis of CDI, glutamate dehydrogenase (GDH) screening test, 56 
toxin A and toxin B EIA testing, and nucleic acid amplification tests (NAATs) for 57 
toxin genes are recommended[7].  58 
  Although the sensitivities of NAATs were higher than that of the EIA test, it was 59 
difficult to conduct NAATs on all specimens in routine examinations, because of the 60 
high cost and labor involved. The first European Society of Clinical Microbiology and 61 
Infectious Diseases (ESCMID) guideline recommend a two-step algorithm: first, 62 
samples should be analyzed by EIA testing; if the result is positive for GDH and 63 
negative for toxin A/B, samples are then analyzed by NAATs[7]. Recently, the fully 64 
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automated molecular test (FAMT) has been developed, making it easier to perform 65 
NAATs [8,9] and allowing for the detection of CDT. Many hospitals are expected to 66 
implement the NAATs including FAMT, but there have been few molecular 67 
epidemiological studies of C. difficile and CDT in Japan[10–12].  68 
In this study, we investigated the molecular epidemiology of C. difficile. 69 
Additionally, to clarify the patients who were recommended for performance of the 70 
NAATs, we investigated and compared the patients' backgrounds between toxin-71 
positive and -negative C. difficile to clarify the risk factors for CDI.  72 
 73 
  74 
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Materials and Methods 75 
Study design and sample collection 76 
 This study was conducted between January 2012 and December 2014. This study was 77 
approved by the ethics committee of Nagasaki University Hospital (13062425). We 78 
collected C. difficile isolated from stool samples between January 2012 and December 79 
2014 in Nagasaki University Hospital. To avoid duplicates, only the first isolate from 80 
each patient was collected.  81 
  The patient background information, such as age, gender, length of hospitalization, 82 
underlying diseases, history of surgery within 90 days before submission of stool 83 
sample, length of hospitalization before submission of stool sample, oral and 84 
intravenous administration of antimicrobial agents, use of proton pump inhibitors 85 
(PPIs), and use of histamine-2 receptor antagonists (H2 blockers) within 60 days 86 
before submission of stool sample, CDI symptoms associated with CDI, and 87 
mortality rate were analyzed. We defined administration of metronidazole and oral 88 
vancomycin after submission of stool sample as CDI treatment. Because we did not 89 
evaluate the Bristol scale in the laboratory during the study period, we investigated 90 
the development of diarrhea, based on medical record. We also investigated the 91 
laboratory data for white blood cell count (×103/µl), red blood cell count (×106/µl), 92 
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C-reactive protein (CRP) (mg/dl), blood urea nitrogen (BUN) (mg/dl), serum 93 
creatinine (mg/dl), uric acid (UA) (mg/dl), total protein (TP) (g/dl), albumin (g/dl), 94 
and lactate dehydrogenase (LD) (U/l) at one day before and after submission of 95 
the stool sample.  96 
 97 
Genetic analysis 98 
In this study, we used the ATCC9689 strain as a positive control. We inoculated all 99 
C. difficile strains with cycloserine-cefoxitin mannitol agar (CCMA; Nissui 100 
Pharmaceutical Co., Ltd., Japan). The plates were incubated at 37°C for 48–72 h under 101 
anaerobic conditions. Bacterial DNA was extracted by using Achromopeptidase 102 
solution (Wako Chemical Co., Ltd., Osaka, Japan), 10% Chelex-100 (Bio-Rad 103 
Laboratories, Hercules, CA, USA), and the boiling method [13]. We confirmed the 104 
genes for toxins (tcdA and tcdB), CDT (cdtA and cdtB), and 16S rRNA by PCR as 105 
previously described [14]. The 16S rRNA primers were as follows: forward 8UA, 5’-106 
AGAGTTTGATCMTGGCTCAG-3’; and reverse 1458B, 5’-107 
TACGGTTACCTTGTTACGAC-3’ [15]. 108 
PCR ribotyping was evaluated by capillary gel electrophoresis-based PCR, which 109 
was performed according to the protocol of a previous study [16]. In this method, we 110 
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used the Applied Biosystems 3130 genetic analyzer with POP7 polymer (Applied 111 
Biosystems, Foster City, CA, USA) and GeneScan-1200Liz size standard (Applied 112 
Biosystems). The size of each peak was determined using Peak Scanner software v1.0 113 
(Life Technologies, Carlsbad, CA), and PCR ribotypes were determined by the 114 
Webribo database of the Austrian Agency for Health and Food Safety 115 
(https://webribo.ages.at).  116 
We defined a following situation as outbreak, based on the notification from 117 
Regional Medical Care Planning Devision, Healthy Policy Bureau, Ministry of Health, 118 
Labor and Welfare, Japan (December 19, 2014): same PCR ribotype strain was 119 
isolated from three or more patients hospitalized in same ward within 4 weeks.  120 
 121 
Statistical analysis 122 
  The statistical software used in this study was JMP Pro 10.0.2 (SAS Institute Inc, 123 
Cary NC, USA). Continuous variables were compared using the Student’s t-test. The 124 
chi-square was used to compare categorical variables. Variables with a P value less 125 
than 0.20 according to the univariate analysis were considered for inclusion in the 126 
forward stepwise multivariate logistic regression analysis.    127 




Genetic analysis 130 
  C. difficile strains were isolated from a total of 213 (122 men and 91 women) 131 
patients during the study period (Fig. 1). The positive rates of tcdA, tcdB, and CDT 132 
genes were 62.9% (n = 134), 63.4% (n = 135), and 2.8% (n = 6), respectively. We 133 
defined strains harboring the tcdA and/or tcdB genes as toxin gene-positive strains. 134 
Among the toxin gene-positive strains, the positive rate of CDT gene was 4.4%. 135 
  PCR ribotyping was performed on toxin gene-positive strains (Table 1). The most 136 
frequent PCR ribotype was the 047 strain (14.1%), followed by 014/0 (11.1%), 002/0 137 
(8.2%), 020 (6.7%), and 018 (4.4%). The PCR ribotypes of CDT-positive strains were 138 
016 (two strains), 131 (three strains), and 413 (one strain). There was no outbreak of 139 





Table1 PCR ribotype of toxin genes-positive strains 
Ribotype (N) (%) 
047 19 14.1  
014/ 0 15 11.1  
002/ 0 11 8.1  
020 9 6.7  
018 6 4.4  
043 5 3.7  
449 5 3.7  
076 4 3.0  
209 4 3.0  
001 3 2.2  
012 3 2.2  
056 3 2.2  
153 3 2.2  
638 3 2.2  
015 2 1.5  
046 2 1.5  
131 2 1.5  
404 2 1.5  
496 2 1.5  
541 2 1.5  
660 2 1.5  
014/ 5 2 1.5  
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Other 26 19.3  
Other: less than 1%   
 143 
Comparison of toxin gens-positive and -negative strains 144 
The patient backgrounds with toxin gene-positive and -negative strains are shown in 145 
Table 2. The average age of the patients was significantly higher in patients with toxin 146 
gene-positive strains (54.2 years) than in those with toxin gene-negative strains (42.4) 147 
(p = 0.0034). There were significant differences between the two groups in terms of 148 
the inpatient department. The percentage of patients with toxin gene-positive strains 149 
who were hospitalized at the Department of Pediatrics was significantly lower in 150 
patients with toxin-positive gene (25 patients, 15.6%) than in those with toxin gene-151 
negative strains (25 patients, 32.1%) (p = 0.0055). In contrast, the percentage of 152 
patients with toxin gene-positive strains who were hospitalized at the Department of 153 
Digestive Surgery was significantly higher than in patients with toxin-positive gene 154 
strains (27 patients, 20.0%) than in those with toxin gene-negative strains (four 155 
patients, 5.2%) (p = 0.0015). When analyzing the laboratory data, the serum albumin 156 
levels in patients with toxin gene-positive strains was significantly lower (3.0 ± 0.7 157 
g/dl) than in those with toxin gene-negative strains (3.3 ± 0.7 g/dl) (p = 0.0017).  158 
Administration of antimicrobials, PPIs, and H2 blockers and antimicrobial agents is 159 
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summarized in Table 3. The PPIs, H2 blockers, and antimicrobial agents were 160 
administered to 84 patients (39.4%), 15 patients (7.0%), and 157 patients (70.5%), 161 
respectively. The percentage of those administered with macrolides was significantly 162 
higher in the patients with toxin gene-positive strains (seven patients, 5.2%) than in 163 
those with gene-negative strains (0 patients, 0.0%) (p = 0.0107).  164 
 165 




(n = 213) 
Patients with toxin 
genes-positive 
strain (n = 135) 
Patients with toxin 
genes-negative 
strain (n = 78) 
P value 
Age 49.9 ± 28.4 54.2 ± 26.5 42.4 ± 29.9 0.0034 
 < 15 years old 49 (23.0 %) 23 (17.0 %) 26 (33.3 %) 0.0072 
 ≥ 65 years old 91 (42.7 %) 66 (48.9 %) 25 (32.0 %) 0.0159 
Sex (male %) 122 (57.3 %) 80 (59.3 %) 42 (53.8 %) 0.4422 
length of hospitalization (day) 32.3 ± 55.8 33.2 ± 60.2 30.6 ± 47.2 0.9466 
diarrhea (%) 128 (60.1 %) 83 (61.5 %) 45 (57.7 %) 0.5869 
abdominal tenderness 59 (27.7 %) 39 (28.9 %) 20 (25.6 %) 0.6086 
temperature (≥ 38.5 °C) 49 (23.0 %) 29 (21.5 %) 20 (25.6 %) 0.4893 
previous surgery within 90 
days 
36 (16.9 %) 25 (18.6 %) 11 (14.1 %) 0.4023 
mortality within 90 days 24 (11.3 %) 15 (11.1 %) 9 (11.5 %) 0.9244 
Treatment with CDI 
(vancomycin or 
metronidazole) 
44 (20.7 %) 33 (24.4 %) 11 (14.1%) 0.0663 
Department      
 Hematology 47 (22.1 %) 30 (22.2 %) 17 (21.8 %) 0.9422 
 Pediatrics 46 (21.6 %) 21 (15.6 %) 25 (32.1 %) 0.0055 
 Gastroenterology 44 (20.7 %) 28 (20.7 %) 16 (20.5 %) 0.9684 
 Digestive Surgery 31 (14.6 %) 27 (20.0 %) 4 (5.2 %) 0.0015 
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 Respiratory medicine 11 (5.2 %) 9 (6.7 %) 2 (2.6 %) 0.1700 
 Anesthesiology 7 (3.3 %) 4 (3.0 %) 3 (3.9 %) 0.7302 
Disorder     
 Hematology 54 (25.4 %) 33 (24.4 %) 21 (26.9 %) 0.6895 
 Liver 41 (19.2 %) 26 (19.2 %) 15 (19.2 %) 0.9959 
 Kidney 12 (5.6 %) 7 (5.2 %) 5 (6.4 %) 0.7110 
 Intestinal diseases 27 (12.7 %) 21 (15.7 %) 6 (7.7 %) 0.0858 
 cardiac 12 (5.6 %) 9 (6.7 %) 3 (3.9 %) 0.3767 
Laboratory data     
 White Blood Cell (×103/ µl) 7.5 ± 6.6 7.4 ± 6.2 7.7 ± 7.4 0.9546 
 Red Blood Cell (×106/µl) 3.4 ± 0.8 3.4 ± 0.7 3.5 ± 0.8 0.3977 
 C-reactive protein (mg/dl) 5.1 ± 6.1 5.8 ± 6.5 3.9 ± 5.1 0.0565 
 Blood urea nitrogen (mg/dl) 19.1 ± 15.0 19.8 ± 16.4 17.8 ± 11.9 0.5033 
 Serum creatinine (mg/dl) 0.9 ± 1.1 1.0 ± 1.0 0.9 ± 1.3 0.0659 
 Uric acid (mg/dl) 4.5 ± 2.3 4.8 ± 2.6 4.2 ± 1.7 0.6126 
 Total protein (g/dl) 6.2 ± 1.0 6.2 ± 1.0 6.4 ± 0.9 0.2012 
 Albumin (g/dl) 3.1 ± 0.7 3.0 ± 0.7 3.3 ± 0.7 0.0017 
 Lactate dehydrogenase 
(U/l) 
246.9 ± 160.6 244.0 ± 179.9 252.5 ± 116.2 0.1717 
 166 
Table3 Comparison of administration of PPI, H2 blocker and antimicrobial agents between the 
patients with toxin genes-positive and negative strains 
Variable 
Total  
(n = 213) 
Patients with toxin 
genes-positive 
strain (n = 135) 
Patients with toxin 
genes-negative 
strain (n = 78) 
P value 
PPIs 84 (39.4 %) 54 (40.0 %) 30 (38.5 %) 0.8247 
H2 blocker 15 (7.0 %) 9 (6.7 %) 6 (7.7 %) 0.7793 
Administration of antimicrobial 
agents within 60 days 
157 (73.7 %) 102 (75.6 %) 55 (70.5 %) 0.4288 
Penicillin 49 (23.0 %) 31 (23.0 %) 18 (23.1 %) 0.9848 
Cephalosporin 81 (38.0 %) 51 (37.8 %) 30 (38.5 %) 0.9211 
 1st generation Cephalosporin 17 (8.0 %) 12 (8.9 %) 5 (6.4 %) 0.5139 
 2nd generation Cephalosporin 7 (3.3 %) 3 (2.2 %) 4 (5.1 %) 0.2625 
 3rd generation Cephalosporin 15 (7.0 %) 12 (8.9 %) 3 (3.8 %) 0.1478 
 4th generation Cephalosporin 48 (22.5 %) 28 (20.7 %) 20 (25.6 %) 0.4124 
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Carbapenems 64 (30.0 %) 40 (29.6 %) 24 (30.8 %) 0.8614 
Aminoglycoside 7 (3.3 %) 4 (3.0 %) 3 (3.8 %) 0.7302 
Fluoroquinolones 30 (14.1 %) 20 (14.8 %) 10 (12.8 %) 0.6852 
Macrolides 7 (3.3 %) 7 (5.2 %) 0 (0.0 %) 0.0107 
PPI, proton pump inhibitors     
 167 
Risk factor for detection of toxin gene-positive strains 168 
We compared the background of the patients with toxin gene-positive and -negative 169 
strains by univariate and multivariate analyses to clarify the risk factors for the 170 
detection of toxin gene-positive strains (Table 4). In the univariate analysis, the risk 171 
factors for the detection of toxin genes positive-strain were older age (OR, 0.99; 95% 172 
CI, 0.98–1.00; p = 0.0036), over ≥ 65 years old (OR, 2.03; 95% CI, 1.13–3.63; p = 173 
0.0175), patients hospitalized at the Department of Digestive Surgery (OR, 4.63; 95% 174 
CI, 1.55–13.8; p = 0.0059), higher CRP level (OR, 0.94; 95% CI, 0.89–1.00; p = 175 
0.0395), and lower albumin level (OR, 2.02; 95% CI, 1.29–3.14; P = 0.0014). In the 176 
multivariate analysis, the risk factors for the detection of toxin gene-positive strains 177 
were patients hospitalized at Department of Digestive Surgery (OR, 4.62; 95% CI, 178 
1.18–18.0; p = 0.0274).  179 




Table4 Univariate and multivariate analysis of the risk factor for the detection of toxin genes-
positive strains 
Risk factor 
Univariate analysis Multivariate analysis 
Odds 
ratio 
95 % CI P value 
Odds 
ratio 
95 % CI P value 
Age 0.99  0.98-1.00 0.0036 1.01 0.96-1.06 0.7574  
< 15 years old 0.41  0.21-0.79 0.0073 - - - 
≥ 65 years old 2.03  1.13-3.63 0.0175 1.67 0.44-6.37 0.4495  
Department of Pediatrics 0.39  0.20-0.76 0.0056 - - - 
Department of Digestive 
Surgery 
4.63  1.55-13.8 0.0059 4.62 1.18-18.0 0.0274  
Intestinal diseases 2.21  0.85-5.74 0.1032 1.28 0.38-4.28 0.6915  
C-reaction protein (mg/dl) 0.94  0.89-1.00 0.0395 0.97 0.91-1.04 0.3974  
Albumin (g/dl) 2.02  1.29-3.14 0.0014 1.51 0.80-2.84 0.2010  
Administration of 3rd 
generation Cephalosporin 
within 60 days 
2.44  0.67-8.93 0.1478 7.22 0.85-61.0 0.0694  
 Multivariate analysis; Predictors with a P value < 0.20 in the univariate analysis were included in 
forward stepwise multivariate logistic regression analysis. 
 182 
Characteristics of the patients with CDT gene-positive strains 183 
 CDT gene-positive strains were cultured from 6 patients (3 men and 3 women). The 184 
age range was 5–84 years, and the patients under 18 years included 2 patients. All 185 
patients had diarrhea, 3 had temperatures of over 38.5°C, and the white blood cell 186 
count was high only in one case (29,700/µl). There were no severe cases, such as 187 
pseudomembranous enteritis, in the 6 patients. Treatment with CDI (vancomycin or 188 




 This study revealed the molecular epidemiology of C. difficile and risk factors for 191 
the detection of toxin gene-positive strains. In a previous Japanese study, the 192 
percentage of toxin gene-positive strains and CDT gene-positive strains was 73% and 193 
2%, respectively [10]. In other Japanese study, CDT-gene positive strains was 5% [17]. 194 
In comparison with the previous studies, the percentage of toxin gene-positive strains 195 
that was lower than that of CDT gene-positive strains was nearly the same in this study. 196 
The lower percentage of toxin gene-positive strain was caused by a difference in 197 
collection of samples. The previous report investigated suspected CDI, but in this 198 
study, we investigated all strains cultured from stool samples. Therefore, our study 199 
involved the patients with colonization of C. difficile. The percentage of CDT gene-200 
positive strain in Japan seemed to be lower than that in other countries: the percentage 201 
of CDT gene-positive strain in Colombia was 17.5% [18]; in United Kingdom and 202 
Finland, the percentage of CDT gene-positive strains was 16.9% and 37%, 203 
respectively. [19,20]. Additionally, in this study, we did not detect NAP1/027 and 078 204 
strains, which were reported as the causative pathogens of serious and epidemic CDI in 205 
Europe and United States [21]. The PCR ribotype of CDT gene-positive strains in this 206 
study was 016, 131, and 413.  207 
18 
 
 In this study, we clarified the PCR ribotype in all toxin gene-positive strains. The 208 
most frequent ribotypes as revealed by PCR for toxin gene-positive strains were 047, 209 
014/0, and 020 in this study. In a previous Japanese study, the ribotypes present at a 210 
high frequency were strains 018, 002, 052, and 369 [22]. In other Japanese study, the 211 
ribotypes present at a high frequency was strains 449 [17]. The frequent PCR ribotypes 212 
varied by the studies in Japan [17, 22]. In the United States, the most frequent PCR 213 
ribotypes were strains 002, 014-020, 027, and 053-163 [23], but the most frequent 214 
PCR ribotypes were different according to area. Other reports from the United States 215 
revealed that the most frequent PCR ribotypes in the northeast, southern, midwestern, 216 
and western United States were 027, 014/020, 106, 001, 053, respectively [24]. We 217 
hypothesized that ribotypes differed from area to area, and that it is important to 218 
conduct surveillance in each area. Additionally, 42% of the PCR ribotype strain 047 219 
was detected from the patients at Department of Digestive Surgery in this study, but 220 
we did not observe outbreak of the strain. This result was indicating that epidemic 221 
ribotypes differed from ward to ward. 222 
 We investigated the risk factors for the detection of toxin-positive strains by 223 
comparing the characteristics of patients with toxin gene-positive and negative strains. 224 
In the univariate analysis, there was no significant difference in the administration 225 
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history of the antimicrobial drugs or the type of antibiotics between the patients with toxin 226 
gene-positive and -negative strains. Since the antimicrobial drug administration history 227 
was observed at almost the same ratio in both groups, administration of antimicrobial 228 
drugs may lead to the colonization of C. difficile. In the analysis of laboratory data, the 229 
patients with toxin gene-positive strains showed higher CRP and lower albumin levels. 230 
However, there were no significant differences in the multivariate analysis. It seems to be 231 
difficult to discriminate between the presence or absence of toxin gene-positive strains by 232 
using laboratory data. In the multivariate analysis, the risk factors for the detection of 233 
toxin gene-positive strains included hospitalized patients at the Department of 234 
Digestive Surgery. On the other hand, if C. difficile was detected in children, the 235 
possibility that they were also positive for toxin genes was relatively low in this study. 236 
A previous report revealed that CDI was more frequently caused in solid-organ 237 
transplant recipients than in other hospitalized patients, because solid-organ transplant 238 
recipients had a several CDI risk factors, such as PPIs, H2 blockers, age greater than 65 239 
years old, severe underlying disease, uremia, gastrointestinal surgery, presence of 240 
nasogastric or endotracheal tube, and prolonged hospitalization [25]. The Department 241 
of Digestive Surgery in our hospital conducts solid-organ transplants, and it seemed 242 
to have had an influence on the higher percentage of toxin gene-positive strains in the 243 
20 
 
Department of Digestive Surgery. 244 
There were some limitations in this study. First, we studied only C. difficile strains 245 
cultured from stool samples, and CDIs diagnosed by only enzyme immunoassays were 246 
not included in this study. Second, we could not investigate the Bristol scale. If we 247 
could investigate the Bristol scale, we would evaluate the association between 248 
diarrhea condition and harboring toxin genes including Bristol scale. Third, we did 249 
not determine the PCR ribotype of toxin gene-negative strains. The PCR ribotype of 250 
the toxin gene-negative strains remained unknown. It is necessary to understand the 251 
tendency to colonized C. difficile with toxin negative strains. Therefore, further 252 
investigations are needed.  253 
 254 
Conclusion 255 
In this study, the percentages of toxin gene-positive and CDT gene-positive strains 256 
were almost the same as those reported in previous studies, but the ribotypes differed. 257 
In addition, we revealed that the risk factors associated with the detection of toxin 258 
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Figure legend 356 
Fig 1. Analysis of C. difficile isolates 357 
C. difficile isolated from stool sample of 213 patients were analyzed for toxin genes by multiplex PCR. 358 
Toxin genes-positive strains were analyzed for PCR ribotype (n = 135). 359 
